Neurobehavioral Signatures of Sign- and Goal-Tracking in Emerging Adults: Translation of a Preclinical Model
NCT ID: NCT07094061
Last Updated: 2025-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
294 participants
INTERVENTIONAL
2025-10-03
2027-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis:
\- A stronger sign-tracking bias will be associated with a bottom-up processing style characterized by less adaptive attentional- and impulse-control as well as hyperactive reward processing, whereas a stronger goal-tracking bias will be associated with a top-down processing style characterized by strong attentional- and impulse-control as well as normative reward processing.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Task Development and Implementation for Functional MRI Studies
NCT01036685
Endophenotyping With Functional Magnetic Resonance Imaging (fMRI)
NCT01503931
Using Neurofeedback to Understand the Relationship Between Stress and Alcohol Consumption
NCT06247306
Neurobiological Substrate of Social Context on Cognitive Control in Drug Users
NCT03508362
FMRI of Stress and Addictive Disorders
NCT01558973
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Assessment group
fMRI
Participants will have an MRI to scan participants brains and will wear skin conductance electrodes on the hand and fill out questionnaires. Scanning will take approximately 90 minutes. While lying in the scanner, participants will be asked to perform some tasks. The tasks will be presented to participants visually on a screen in the scanner and eye movements will also be tracked during some of these tasks. Participants will respond to stimuli with button presses that are recorded by computer.
Questionnaires and surveys
Participants will have multiple visits during this study and fill out various surveys at these visits.
Behavioral tasks and eye tracking
Participants will perform behavioral tasks while having eye-tracking hardware monitor participants eye movements. A video camera will be used to record eye movements during the behavioral tasks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
fMRI
Participants will have an MRI to scan participants brains and will wear skin conductance electrodes on the hand and fill out questionnaires. Scanning will take approximately 90 minutes. While lying in the scanner, participants will be asked to perform some tasks. The tasks will be presented to participants visually on a screen in the scanner and eye movements will also be tracked during some of these tasks. Participants will respond to stimuli with button presses that are recorded by computer.
Questionnaires and surveys
Participants will have multiple visits during this study and fill out various surveys at these visits.
Behavioral tasks and eye tracking
Participants will perform behavioral tasks while having eye-tracking hardware monitor participants eye movements. A video camera will be used to record eye movements during the behavioral tasks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed
* Medically/physically able to give informed consent
* English-speaking
* Substance use is free to vary, but for participants with a history of substance use, ≥ 1 use of cannabis (including less than a full dose)
Exclusion Criteria
* History of psychosis in self or first-degree relative
* Current treatment for substance use disorder
* Current or past 6-month treatment with centrally acting medications (not including attention deficit hyperactivity disorder (ADHD) medication)
* Intelligence quotient (IQ) \< 70
* Lifetime history of head trauma with loss of consciousness \> 5 minutes
* Reliance on glasses to be able to read small text at a distance of approximately 30 inches
* Colorblindness
* MRI contraindication (e.g., pregnancy, metal implants, claustrophobia) per protocol
18 Years
20 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
University of Michigan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lora Cope
Assistant Professor Psychiatry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lora Cope, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Michigan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rachel Upjohn Building
Ann Arbor, Michigan, United States
University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HUM00269332
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.